Tryp completes their Phase 2a psilocybin for IBS clinical trial training for psychotherapists at Massachusetts General Hospital.
This week in psychedelic stock news: MindMed downplays delisiting fears; Red Light Holland teams with Wiz Khalifa; Field Trip shareholders approve company split; and more!
This week in psychedelic business news: Field Trip Health splits in two, Tryp Therapeutics commences study, and Optimi Health celebrates new facility.
This week in psychedelic business news: FDA green lights a new psilocybin study; MindMed commences LSD treatment for ADHD; Sage Institute shuffles leadership.
The pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs estimates a $2.9 billion market potential for such a treatment.
This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher partners with Revive Therapeutics on microneedle patch technology; Mydecine patents nanotechnology.
This week in psychedelic business news: Psychedelics in development to treat eye diseases and stroke; companies gear up for new clinical trials investigating psychedelics for general anxiety, chronic pain, and eating disorders.
This week in psychedelic business news: It’s all about partnerships and acquisitions designed to advance psychedelic therapies for depression, suicidal ideation, pain, and more.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.